IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.94−0.65 (-1.60%)
Close on Nov 19, 2026Market cap $40.62MP/E –Yield –
IRulya Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
IRulya Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$47.00M. For fiscal 2025 it was -$41.78M. The highest annual figure on record is -$11.91M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.78M | – |
| FY2024 | Dec 31, 2024 | -$32.16M | – |
| FY2023 | Dec 31, 2023 | -$18.45M | – |
| FY2022 | Dec 31, 2022 | -$44.17M | – |
| FY2021 | Dec 31, 2021 | -$63.11M | – |
| FY2020 | Dec 31, 2020 | -$50.87M | – |
| FY2019 | Dec 31, 2019 | -$33.33M | – |
| FY2018 | Dec 31, 2018 | -$11.91M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.89M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.69M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.78M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.82M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.10M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.34M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.65M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.39M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.78M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.82M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.28M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.27M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.97M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.12M | – |
See a number that looks wrong?